Inherently fluorescent and porous zirconia

colloids : preparation, characterization and drug

adsorption studies by Naszályi Nagy, Lívia et al.
This journal is©The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 7529--7537 | 7529
Cite this: J.Mater. Chem. B, 2015,
3, 7529
Inherently fluorescent and porous zirconia
colloids: preparation, characterization and drug
adsorption studies†
L. Nasza´lyi Nagy,*a J. Miha´ly,a A. Polyak,b B. Debreczeni,a B. Csa´sza´r,ac
I. Cs. Szigya´rto´,a A. Wacha,a Zs. Cze´ge´ny,a E. Jakab,a Sz. Kle´bert,a E. Drota´r,a
G. Dabasi,d A. Bo´ta,a L. Baloghb and E´. Kissc
Porous, fluorescent zirconia particles of nearly 380 nm diameter were prepared without template molecules
or labeling dyes. The porous structure is the result of aggregation-induced particle formation. The inherent
fluorescence is assigned to coordinatively unsaturated Zr4+ ions at the sol–gel derived ZrO2 surface. After
physico-chemical characterization of the native zirconia particles carboxyl and/or amine bearing drug mole-
cules (D,L-a-difluoromethylornithine – DFMO, ursolic acid – UA and doxorubicin – DOX) were adsorbed
onto their surface, and the products were analyzed with Fourier-transform infrared spectroscopy (FTIR),
thermogravimetry (TG), small-angle X-ray scattering (SAXS), fluorimetry and zeta potential vs. pH measure-
ments. We have found that DOX complexes coordinatively unsaturated Zr4+ ions without dislocating them,
while carboxyl-bearing drugs interact with basic surface Zr–OH sites eliminating some of the carbonate
species. The adsorption of UA at the zirconia surface shifts considerably the isoelectric point of the surface
and thus provides kinetic stability to the particles at physiological pH. An in vivo biodistribution study in
two healthy dogs performed by SPECT/CT detection after 99mTc labeling of the nanocarriers has shown
the possibility of drug delivery application.
Introduction
Nano- and microparticles of various kinds are currently inves-
tigated with the prospect of drug delivery application. The
requirements to be fulfilled are numerous: drug carrier parti-
cles should encapsulate, transport and release drug molecules
in a controlled way in living organism.1 Multifunctionality is,
therefore, inevitable and – when coupled to easy synthesis –
represents a great advantage. Among inorganic particles
silica2,3 is preferred for its controlled synthesis, low toxicity,
established conjugation methods and high drug loading capa-
city (for mesoporous silica).
Zirconia, a ceramic material, is used for biomedical applica-
tions e.g. in dental and chirurgical implants.4–6 It is known to
be biocompatible, and we have shown in our preliminary
experiments that zirconia is also biodegradable under certain
circumstances. The surface of zirconia is chemically active,
having both acidic and basic sites.7 This explains that zirconia
chemisorbs both NH3 and CO2.
8 Under ambient conditions, the
zirconia surface is always covered by CO and CO2 adsorbed from
the air.9,10 Complex formation has also been observed with the
carboxyl groups of citric acid and poly-e-caprolactone.11,12 As was
observed by Pokrovski et al. CO2 adsorption on monoclinic (m-)
ZrO2 is more than an order of magnitude higher than that on
tetragonal (t-) ZrO2.
13 High-temperature synthesis or annealing
of ZrO2 leads to the transformation of the monoclinic phase into
tetragonal.
However, the lack of a generally approved synthetic method
providing stable m-ZrO2 colloid hinders its use as a drug
carrier. Nanocrystalline powders of t-ZrO2 are produced by
aqueous phase reaction followed by annealing.14–17 These
materials sintered by a final annealing cannot be suspended
to yield a stable uniform colloid. Spherical m-ZrO2 are obtained
from alkoxide precursors in alcohol after controlled hydrolysis
and condensation.18–20 The diameter of these particles is
usually over micrometer, and could only be reduced down to
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200 nm by the addition of monovalent metallic cations.20 For a
nano-sized object, the use of a template is necessary,21,22
however, this involves multi-step preparation.
In this paper we investigated the possibility of obtaining
multifunctional: porous and fluorescent zirconia particles in
one single synthetic step that are able to adsorb significant
quantity of drug.
We intended to induce both porosity and fluorescence in
ZrO2 starting from the method of Widoniak et al.
20 where these
functionalities were not described. Zhang and coworkers
described cetyl trimethylammonium bromide (CTAB) induced
fluorescence in ZrO2 powders.
23 Zelcer et al. have produced
mesoporous ZrO2 thin films with ordered porosity using
Pluronics, Brij58 or CTAB as a template.24 The surfactant was
eliminated in both procedures by annealing that we wished to
avoid. We carried out preliminary experiments with CTAB
templating as well, and tried to eliminate the surfactant by
excessive washing. The structure and fluorescence of the
obtained materials are compared and discussed in this paper.
Finally, the affinity of the obtained zirconia particles for
carboxyl and/or amine bearing drug molecules was studied.
For this study, three anticancer drug molecules were chosen:
D,L-a-difluoromethylornithine (DFMO, also known as eflornithine),
doxorubicin (DOX) and ursolic acid (UA). There is a significant
difference between them in several aspects: structure, solubility,
acidity (Table 1).
In short, DFMO is a highly water soluble, nontoxic small
molecule, whose main disadvantage is its rapid clearance from
the body, therefore its clinical use for cancer treatment was
stopped. DOX is a cardiotoxic drug, whose nanoformulated
products are proven to be more efficient and less harmful than
its free form.30 UA is a natural anticancer compound,31,32 whose
very low water solubility prevents its use in pharmaceutics.27
The structure of drug loaded ZrO2 particles was examined with
SAXS in the present work. The affinity of DFMO, DOX and UA for
the zirconia surface was investigated using TG, zeta potential-pH
curves, and FTIR spectroscopy. The changes induced by drug
adsorption in the porous and fluorescent properties of zirconia
particles were also examined. Additionally, as ursolic acid loaded
particles proved to be stable in physiological medium, they were
radiolabelled with a technetium-99m (99mTc) isotope. As labelling
stability was excellent, normal biodistribution studies were per-
formed in two healthy Beagle dogs using SPECT/CT imaging in
order to prove in vivo particle size stability of NPs and verify the
ability of the method to carry out prospective in vivo follow-up
investigations of the drug delivery process.
Experimental section
Materials
Absolute ethanol (a.r., 499.7%,o0.2% water, Reanal), cesium
chloride (CsCl, Specpure, trace metal basis), and zirconium(IV)
butoxide (TBOZ, 80 wt% in butanol, Sigma-Aldrich) were used
for the optimized synthesis of ZrO2. TBOZ was kept and manipu-
lated under argon gas. Cetyl trimethylammonium chloride (CTAB,
Z99%, Acros Organics) was used in preliminary experiments for
the induction of fluorescence and porosity. Ultrapure water was
collected from a MilliQ System. D,L-a-Difluoromethylornithine
called also eflornithine (DFMO or E Z97%, Sigma), doxorubicin
hydrochloride (DOX, 98.0%, Calbiochem) and ursolic acid (UA,
Z90%, Sigma-Aldrich) were used as received. Doxorubicin was
kept in dark at 4 1C. Methyl ethyl ketone (MEK, Reanal) was used
for thin layer chromatography.
Preparation of zirconia particles
The synthesis route described by Widoniak et al.20 was used
with modifications. Briefly, a magnetic stirrer with oil bath,
glassware, pipettes and reagents were put in a glove box.
Freshly prepared 0.1 M CsCl solution was put in a screw cap
vial. 100 ml of abs. ethanol was poured into a 250 ml glass vial,
stirred at 300 rpm with a triangle stir bar and heated to 60 1C.
The glove box was closed and flushed with argon. 0.4 ml CsCl
solution was pipetted into the ethanol. After homogenization
3.25 ml of TBOZ was quickly added to it and the glass vial was
closed. The solution became white within one minute.
Next day the sol was centrifuged three times at 4000 rpm
(10 min). The supernatant was discarded and the sediment was
resuspended in ethanol by means of an ultrasonic homogenizer
(150VT, BioLogics) (solid content: 8.3  0.8 mg ml1; mean and
standard deviation of 3 parallel measurements). The product
was kept at 4 1C.
Drug adsorption
5  106 mol DFMO (in powder), DOX (dissolved in 2.3 ml
water) and UA (dissolved in 3.8 ml ethanol) were added to
5 ml of ZrO2 sol (64 mg ZrO2). The mixtures were stirred
(in dark for doxorubicin) for 3 days, and then they were centri-
fuged (4000 rpm, 18 min). The sediment was rinsed with 3 ml of
water and centrifuged a second time. The particles were finally
resuspended in 5 ml water. Samples with adsorbed drug were
labelled ZE (DFMO), ZD (doxorubicin) and ZU (ursolic acid).
The maximum drug encapsulation was determined adding
0.306 mmol drug in 2 ml ethanol to 300 ml ethanolic sol (2 mg of
ZrO2), stirring in dark for 3 days, centrifuging and analysing the
supernatant.
Characterization
Structure and morphology of zirconia particles. Morpho-
logical investigation of the nanocarriers was carried out on
a MORGAGNI 268(D) (FEI, Eindhoven, Netherlands) trans-
mission electron microscope (TEM). The diluted ZrO2 sample
was dropped and dried on carbon coated copper grids.
Table 1 Properties of chosen drug molecules
Drug
Solubility in
water (g l1) log P
pKa
strongest
acidic
pKa
strongest
basic
DFMO25 D,L-a-difluoro-
methylornithine, alias
eflornithine
50.0 2 2.19 10.2
DOX26 doxorubicin 1.18 1.41 9.53 8.94
UA ursolic acid 0.07627 6.4328 5.2929
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Nitrogen physisorption measurements were performed at
77 K (196 1C) using a static volumetric apparatus (Quanta-
chrome Autosorb 1C analyzer). The samples were previously
degassed at 423 K (150 1C) for 30 h. Nitrogen adsorption data
were obtained using ca. 0.1 g of the sample and successive
doses of nitrogen until p/p0 = 1 relative pressure was reached.
Only the nitrogen adsorption volumes up to a relative pressure
of 0.1 were considered in the micropore size distribution.
Powder X-ray diffraction was performed on a Philips PW
3710 diffractometer equipped with a PW 1050 Bragg Brentano
goniometer, a graphite monochromator and a proportional
counter. Cu Ka radiation was used as a source.
Small-angle X-ray scattering (SAXS) measurements were
made on a laboratory-built CREDO (Creative Research Equip-
ment for Diffraction) apparatus.33 X-rays were supplied by a
GeniX3D Cu ULD integrated beam delivery system (Xenocs SA,
Sassenage, France). The highly monochromatic Cu Ka radiation
(0.15418 nm wavelength) was collimated by three pinholes of
sizes 300, 300 and 400 mm diameter. A small amount of dry
powder from each sample was fixed between two layers of
scotch tape and mounted onto the standard sample holder.
SAXS patterns were recorded using a Pilatus-300k CMOS hybrid
pixel two-dimensional position sensitive detector (Dectris Ltd,
Baden, Switzerland) at two different sample-to-detector dis-
tances: 457 and 1218 mm, in order to cover a wide range in
the scattering variable (q = 4p sin y/l where 2y is the scattering
angle). The scattering patterns were corrected and calibrated
using the on-line data reduction procedure implemented in the
instrument control software. Subsequently, scattering patterns
were azimuthally averaged, and the resulting one-dimensional
scattering curves were scaled together in intensity and merged,
yielding for each sample a single scattering curve covering the
whole experimentally attainable angular range.
DLS measurements were carried out in a Malvern Zetasizer
(NanoZS90, Malvern, Worcs, UK) equipped with a He–Ne laser
(l = 633 nm) and a backscatter detector at a fixed angle of 1731.
Input parameters were: refractive index of ZrO2 of 2.221,
absorption coefficient of ZrO2 of 0.1, refractive index of ethanol
of 1.359, viscosity of 1.200 Pas, 20 1C. Twenty runs of 10 seconds
each were recorded. The number weighted size distribution
function was presented.
Drug adsorption studies. The pH dependent zeta potential
values of the samples were recorded on the above Malvern
apparatus at 20 1C. 0.5 ml ZrO2, ZE, ZD and ZU suspensions in
water were added 1 ml of 0.01 M NaCl solution (final conc.
1 mM NaCl), and the samples were diluted to 10 ml. The pH
was set to 3 with 0.1 M HCl solution, and then 0.1 M NaOH
solution was used to adjust pH values between 3 and 10
(JENWAY 3540 Bench Combined Conductivity/pH Meter). Each
symbol on the z-pH plot stands for the average and error of
three measurements.
Drug adsorption at ZrO2 surface was demonstrated with
attenuated total reflection infrared (ATR-FTIR) spectroscopy
using a Varian Scimitar 2000 FTIR spectrometer (Varian Inc.)
equipped with an MCT (mercury–cadmium–telluride) detector
and a single reflection ATR unit (‘Golden Gate’, SPECAC Ltd, UK)
with a diamond ATR element. Scans were performed in the
wavenumber region 4000–500 cm1. In general, 4 cm1 resolu-
tion and records of 128 scans were applied.
Maximum drug loading was measured from the supernatant
of drug loaded samples by UV-visible (DOX and DFMO) or
ATR-FTIR (UA) spectroscopies. The picrylsulfonic acid colori-
metric test was performed for the determination of eflor-
nithine: to 500 ml supernatant was added 500 ml 0.1 M borate
buffer (pH 9.28) and 25 ml 0.284 w/v% picrylsulfonic acid
solution in water.
Thermogravimetry (TG) provided information about the
drug content of washed particles. TG measurements were
performed on a modified Perkin-Elmer TGS-2 thermobalance.
About 1 mg sample dried previously at 90 1C for 20 h was placed
into the platinum sample pan and heated at 20 1C min1 up to
700 1C in a 21% oxygen containing argon atmosphere.
Fluorescence of ZrO2, ZE, ZD and ZU samples was measured
on a Shimadzu RF-5301PC spectrofluorimeter after 50-fold
dilution of sols in water (0.256 mg ml1 ZrO2 resulting solid
content). Excitation and emission slit widths were 3 nm. Spectra
were recorded with 1 nm resolution. The excitation wavelength
was 274 nm.
Radiolabeling and normal distribution study. Radiolabeling
examination was carried out on ZU particles (99mTc-ZU) via a
previously applied method.34,35 Labeling efficiency of 99mTc-ZU
particles was checked by thin layer chromatography using
ITLC-SG plates (Agilent Technologies) with MEK eluent. In
order to verify in vivo particle size stability and 99mTc-binding
stability of the product, SPECT/CT imaging investigations were
performed in a human SPECT/CT system (AnyScan, Mediso Ltd,
HU). Injected animals were two healthy Beagle dogs, the
injected activity and volume of the product was 480 MBq in
900 ml. After the intravenous (i.v.) application anaesthesia was
induced, and 30 min later whole body SPECT/CT imaging was
carried-out. Image fusion and quantitative analysis (thyroids,
lungs, heart, liver, kidney and, urinary bladder uptakes) of
99mTc-ZU particles distribution was performed using region of
interest analysis (ROI, Interview software, Mediso Ltd, HU).
Animals were kept and treated in compliance with all applic-
able sections of the Hungarian Laws No. XXVIII/1998 and LXVII/
2002 on the protection and welfare of animals and animal
welfare directions and regulations of the European Union.
Results and discussion
Structure and morphology of zirconia particles
The zirconia samples obtained in ethanol by controlled hydro-
lysis and condensation of zirconium(IV) butoxide possess a
particle diameter over micrometer.19,20 The process is a multi-
step reaction as detailed by Widoniak et al.20 after hydrolysis of
the metalorganic precursor small crystallites form, whose
aggregation provides large secondary particles. The last reac-
tion step is demonstrated by the whitening of the reaction
mixture (usually within 1–5 min). According to our XRD and
FTIR measurements, the small zirconia crystallites of 2.5 nm
Journal of Materials Chemistry B Paper
Pu
bl
ish
ed
 o
n 
24
 A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
by
 H
un
ga
ria
n 
A
ca
de
m
y 
of
 S
ci
en
ce
s o
n 
24
/0
9/
20
15
 0
8:
37
:2
9.
 
View Article Online
7532 | J. Mater. Chem. B, 2015, 3, 7529--7537 This journal is©The Royal Society of Chemistry 2015
diameter are mainly crystallized in a monoclinic structure
(see the diffractogram in Fig. S1 in the ESI†).
The TEM analysis of Cs+-doped ZrO2 particles has evidenced
particles with nearly 300–400 nm diameter (inset in Fig. 1). The
mean hydrodynamic diameter evaluated from number weighted
size distribution function is 384 nm 80 nm (standard deviation)
(Fig. 1). This Cs+-doped zirconia sol is thereafter called the
Widoniak-type sol.
Induction of porosity in zirconia particles. During preliminary
experiments we carried out CTAB templated syntheses in both
ethanol and water to compare porous properties of the
as-synthesized materials to that of Widoniak-type zirconia. In
water, mesopores were obtained according to TEM observa-
tions, but a bulk material formed instead of spherical particles
(Fig. S2(a) in the ESI†).
Ethanol mediated sol gave rise to nearly 100 nm diameter
particles (Fig. S2(b) in the ESI†). However, when we examined
the porous structure of templated and non-templated ZrO2, we
observed the same pattern on SAXS curves (see Fig. S3(a) in the
ESI†) corresponding to micropores. As the elimination of CTAB
molecules by washing is time- and solvent-wasting, non-
templated (Widoniak-type, with Cs+ ions) synthesis was further
used for the synthesis of microporous zirconia. The effect of
annealing (400 1C, 5 h) has also been studied: the crystallite size
of zirconia has increased to 65 nm, and the prevailing crystal
structure became tetragonal (see diffractograms in Fig. S4 in
the ESI†). The annealed samples were found to be aggregated
and the SAXS curve did not show increased porosity (Fig. S3(b)
in ESI†). The elimination of template molecules by annealing is
therefore unfavourable for drug carrier particle synthesis.
The scattering curve of the Widoniak-type zirconia powder
sample shown in Fig. 2a starts with a power-law part, characteristic
of the surface scattering of the aggregates of the primary ZrO2
particles. A least-squares fit to the starting part of the curve revealed
the power-law exponent to be3.516 0.008, which corresponds to
2.484 surface fractal dimension, reflecting that these larger entities
are composed of the smaller, primary particles.36 The power-law
part is followed by a knee in the scattering pattern, turning later on
into another power-law. This section of the scattering curve is
characteristic of the two-phase system formed by the primary
particles and the pores between them, the curvature describing
the average size, while the power-law carries information on the
fractality. The corresponding parameters can be extracted from the
curve by a least squares fit of an empirical, unified Guinier–Porod
model to this range.37 According to this model we obtain 0.68 
0.06 nm for the radius of gyration, which corresponds to 1.76 nm
0.15 nm equivalent sphere diameter. The power-law exponent is
2.75 0.03, and since its magnitude is less than 3, it corresponds
to pore/mass fractal behaviour (instead of surface fractality), with a
fractal exponent of 2.75  0.03, describing the micropore structure.
The fitting of the two parts of the scattering curves was done
simultaneously, i.e. using the following function:
IðqÞ ¼ Aqa þ Ge
q
2Rg
2
3 if qo q
Bqb otherwise:
8><
>:
Fig. 1 TEM picture and DLS size distribution of Cs+-doped ZrO2 particles.
Fig. 2 (a) SAXS curve (thick black line) of the native ZrO2 sample and its least-squares fit (thin red line) with the model described in Experimental section
and (b) nitrogen adsorption–desorption isotherm of ZrO2 powder and resulting pore size distribution function (inset).
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Here the first term corresponds to the starting power-law describing
the surface scattering of the aggregates, and the second term is the
unified Guinier–Porod model. In this model only the G scaling
factor, the Rg radius of gyration and the b second power-law
exponent are the free parameters, because B and q* are determined
from constraints of continuity in the function and its first derivative.
The microporous structure of Widoniak-type zirconia was con-
firmed by N2 adsorption–desorption experiments (Fig. 2b). The
BET surface area was 16 m2 g1 (the value of C parameter was
466) and the total volume ofmicropores wasB0.007 cm3 g1, which
are consistent with those found by Widoniak et al.20 The maximum
of pore size distribution is at 1.52 nm, which is in very good
agreement with the results found by SAXS. Interestingly, Widoniak
et al. did not remark the microporous structure of the sample.
Induction of fluorescence in zirconia particles. Several
studies have described rare earth doping-induced fluorescence
in zirconia powders,38–43 but they dealt with di- and trivalent
ions that prevent secondary particle formation in our case
(experiments not shown). We therefore studied the method
of Zhang et al. that describes fluorescence induced by
CTAB residues after annealing.23 We annealed a portion of
CTAB-templated zirconia, resuspended the powder in ethanol,
and compared its fluorescence to that of a Widoniak-type sol
(Fig. S5, ESI,† similar solid contents were applied). In additional
experiments (not shown), the fluorescence of several metal-ion
mediated synthesis products was recorded (Pt2+, Pr3+, Ir3+), but
band positions were always the same. We propose therefore that
organic residues (or metal ion impurities) are not the origin of
zirconia fluorescence as published by Zhang et al.23 this photo-
luminescence is an inherent characteristic of sol–gel derived
zirconia particles, probably related to surface defects.
Drug adsorption studies
The fluorescent and microporous Widoniak-type zirconia was
studied as a potential drug carrier particle. DFMO, DOX and UA
were selected as carboxyl and/or amine bearing drug molecules
(DFMO carries both functionalities) and adsorbed at the parti-
cle surface (samples denoted as ZE, ZD and ZU).
The thermogravimetric analysis of dried samples permits us
to separate the weight loss caused by desorption of water from
that caused by the degradation of drug molecules (Fig. 3a).
The maximum of drug loading measured from supernatants
and the drug content of washed particles are presented in
Table 2. High and equal encapsulation efficiencies were observed
from supernatants of the three drugs. Lower encapsulation effi-
ciencies were obtained after washing, and the quantity of
adsorbed drug increased oppositely to their solubility in water
from DFMO to UA. The maximum DOX cargo of ZrO2 particles
is close to the loading observed in the literature for mesoporous
silica particles of similar size (21 m/m%).44
The ATR-FTIR spectrum of native zirconia shows the
presence of hydrogen carbonate (HCO3 at 1629, 1464, 1070
and 842 cm1) and of monodentate carbonate (m-CO3
2 at
1539, 1349, 1070 and 842 cm1) species (Fig. 3b). These species
are characteristic of the non-annealed monoclinic type zirconia
surface.8,9,13 The presence of hydrogen carbonate on the zirconia
surface was further supported by deuterium isotope change experi-
ments: the antisymmetric stretching of (HCO3) (at 1629 cm1)
disappeared and characteristic D2O vibrational bands appeared
after two-day exposition of ZrO2 to D2O vapors (experiments not
shown).
After drug loading, the quantity of adsorbed carbonate
(both bicarbonate and monodentate carbonate) species has
diminished. Characteristic IR bands of UA and DFMO become
visible upon appropriate subtraction of the native zirconia
spectrum from ZU and ZE spectra, respectively (Fig. S6 in the
ESI†). The subtraction is not possible in the case of DOX,
because surface species have been transformed: the new bands
at 1559, 1381 and 1350 cm1 are assigned to bridged carbonate
(Fig. 3b). It is to note that the red doxorubicin solution turns
immediately violet upon addition to zirconia suspension that
suggests strong interactions between drug molecules and the
inorganic surface (see UV-visible spectra in Fig. S7 in the ESI†).
Fig. 3 (a) TG/DTA curves and (b) infrared spectra of the ZrO2 powders before and after drug adsorption.
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In effect, the complexation between doxorubicin’s chinoidal oxy-
gens and neighbouring phenol groups has previously been
described with Mn2+ and Cu2+ ions.45,46 We did not find, however,
any previous mention of the doxorubicin-Zr4+ complex.
We carried out supplementary experiments on the basis of
Abraham’s work.45 100–200–300 mM ZrOCl2 solutions were
made in 100 mM HEPES buffer (pH 8), and DOX solution was
added to each one and to pure HEPES buffer (86 mM final DOX
concentration). In the presence of Zr4+ ions, the solutions
became immediately purple, the same as for native ZrO2 particles
transferred into HEPES from ethanol by centrifugation. However,
when native ZrO2 powder dried at 60 1C was resuspended in
HEPES, DOX did not turn purple upon addition. In this case the
carbonate species at the zirconia surface did not change, as
revealed by FTIR spectroscopy (see FTIR spectra in Fig. S8 in
the ESI†). We assume that the surface area of zirconia is much
reduced upon drying due to irreversible aggregation, and the
number of surface defects providing complexation sites is also
decreased in consequence.
The measurement of zeta potential as a function of pH
is a sensitive method for the investigation of interactions at
the surface of nanoparticles. The isoelectric point (IEP) of
Widoniak-type zirconia is at pH 7.1 (Fig. 4).
This corresponds to the value (7.0–7.3) reported earlier for
pure zirconia.47 The IEP of the ZD sample coincides with that of
pure zirconia. At first sight it seems that DOX does not establish
a direct interaction with the zirconia surface. DFMO shifts
slightly the IEP towards the acidic region (pH 6.5). The largest
shift corresponding to the highest affinity is observed for ursolic
acid, where IEP becomes lower than pH 6. We also remarked
that the surface charge at pH 7.5 (physiological) becomes lower
than 20 mV due to UA adsorption which may provide colloidal
stability for the intended drug carrier at this pH. These findings
let us think that DFMO and UA adsorb directly at the metal oxide
surface, while doxorubicin interacts in an indirect way.
We examined the changes induced by drug adsorption in
luminescent properties of zirconia suspension (Fig. 5). Fluores-
cence emission bands are not shifted upon drug adsorption,
but their intensity varies significantly (the solid content of
samples was identical). In the presence of doxorubicin, the
emission intensity increases, while for the two other drugs it
decreases. These results indicate that the mechanism of
fluorescence does not change upon drug adsorption. The
quantum efficiency is higher when doxorubicin is present.
DOX may inhibit non-radiative recombination or can play the
role of a donor in the fluorescence resonance energy transfer
(FRET) mechanism. However, the latter can be excluded since
the excitation of zirconia is effectuated at much lower wave-
length (B274 nm) than the emission of doxorubicin
(B600 nm).48 In the case of UA, the zirconia surface is sup-
posed to transfer energy to the organic molecule, but the UV
absorption of UA is below 200 nm, therefore FRET quenching
cannot take place. It seems that UA is simply lowering the
number of active sites by adsorbing at active Zr4+ ions or
eliminating carbonates interacting with active Zr4+ ions, while
DOX is decreasing the probability of non-radiative recombina-
tion by complexing coordinatively unsaturated (cus) Zr4+ ions,
or eventually by transforming surface carbonates into bridged
carbonates. DFMO, on the other hand, is supposed to quench
the fluorescence of zirconia through the FRET mechanism,
since its highest wavelength UV absorption band is at 330 nm.
Small-angle scattering curves of the loaded powder samples
are presented in Fig. 6. They have similar features to those of
the native zirconia sample, and the same mathematical models
can be fitted. The results of the least-squares fitting in the case
of all four samples (including the native one) are summarized
in Table S1 (ESI†). The first difference between the loaded and
native samples is the relative weight of the scattering from the
primary particle/micropore system, related to the starting power-
law. This can be characterized numerically by the B/A ratio (accord-
ing to the notation in the fitting function in Experimental section).
Table 2 Drug content and encapsulation efficiency
Max. drug loadinga m/m%
(encapsulation efficiency n/n%)
Drug contentb m/m%
(encapsulation efficiency n/n%)
DFMO 4.8 (87%) 0.65 (38%)
DOX 14.5 (88%) 1.75 (42%)
UA 12.5 (88%) 2.60 (61%)
a From supernatant analysis of 0.306 mmol drug per mg ZrO2.
b From TG of 0.078 mmol drug per mg ZrO2 loaded particles.
Fig. 4 Zeta potential vs. pH curves of the ZrO2 sol before and after drug
adsorption.
Fig. 5 Fluorescent emission curves of the ZrO2 sol before and after drug
adsorption.
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As seen from the table, this ratio is significantly smaller for the
loaded powders. This is expected, as the absolute scattering
weight of the pore system decreases the electron density con-
trast between the pore and the ZrO2 phases decreases, and the
scattering contribution of the aggregates does not change
much. This is also expressed in the fact that the first power-
law exponents do not change significantly, thus the aggregates
retain their surface fractal properties.
The radii of gyration determined from the micropore part do
decrease, however, only slightly. The most prominent change is
found in the case of ZD, where the original, approx. 0.68 nm
radius of gyration decreased to 0.56, corresponding to 1.44 nm
equivalent sphere radius. This decrease in all of the loaded
samples may also be attributed to the filling of the pores. It can
be assumed that the filling substance forms thicker, denser
layers near the pore walls and contained more loosely in the
lumina of the pores.
Definition of surface structures. According to all our
observations, we have constructed model structures for the
interpretation of surface interactions of the three drug
molecules studied (Fig. 7). Here we present the most prob-
able structures, whose presence have either been spectrally
proven or suggested on the basis of FTIR and UV-visible
spectroscopy, fluorimetry, zeta potential results and previous
observations.9,11,13,49 Doxorubicin is proposed to complex
cus Zr4+ ions at the surface without dislocating them. The
origin of luminescent properties may also be cus Zr4+ ions,
but this hypothesis needs further investigation. Because of
surface Zr4+ complexation, the carbonate structure is changed,
and the bridged type of carbonate becomes dominant. The
lack of change in the isoelectric point of ZrO2 might be the
result of an equimolar consumption and formation of surface
negative charges (–O). The amino groups of DOX may enter
into electrostatic interactions with surface carbonate species,
since these are in the ionic from according to FTIR shifts.
DFMO and UA mainly replace surface carbonates by linking
directly to basic sites, but are also supposed to be involved
in H-bonds.
Radiolabeling and normal distribution study
As the zeta potential-pH measurement has shown that the
ZU sample may be stable under physiological conditions an
aliquot of ZU suspension was centrifuged and the particles
were suspended in 10 mM phosphate buffer (pH 7.5). DLS
measurements proved that these particles maintained their
dispersity over a period of 10 days at room temperature
(Fig. S9 in ESI†). Samples were thereafter radiolabelled.
99mTc-radiolabeling proved to be a simple and rapid proce-
dure. Labeling efficiency was above 98% and excellent in vitro
99mTc-binding stability could be observed.
The normal biodistribution of the 99mTc-ZU sample in two
healthy beagle dogs is shown in Fig. 8. During the anaesthesia,
i.v. applications and the SPECT/CT examinations clinical side-
effects were not recorded in the animals.
High liver (44% and 48% of total injected activity) and
urinary bladder uptakes were seen 30 min post i.v. applications.
Moderate accumulations were recorded in the kidneys and
negligible by the thyroids, heart and lungs. The results indi-
cated that the size of injected nanoparticles is strictly lower
than 1000 nm (because of very low detectable accumulation in
the lungs) while NPs have a stable 99mTc-binding capability
(concluded from very low thyroid uptakes).
Fig. 6 SAXS curves (thick lines) of the loaded zirconia samples and the
corresponding least-squares fits (thin lines).
Fig. 7 Proposed surface structures for zirconia (a) before drug adsorption and after (b) doxorubicin, (c) DFMO and (d) ursolic acid adsorption onto the
zirconia surface. Cus stands for ‘‘coordinatively unsaturated’’.
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Conclusions
In conclusion, we have revealed that the synthetic method
elaborated by Widoniak et al.20 yielded inherently fluorescent
and microporous zirconia particles that has not yet been
remarked in the literature. We assume that the inherent
fluorescence observed for colloidal ZrO2 particles originates
from surface defects (possibly coordinatively unsaturated Zr4+
ions), whose number decreases upon aggregation, drying and
annealing of the particles. Despite the great structural differences
in their molecular structure, carboxyl-bearing DFMO and UA
identically link to basic surface sites eliminating some of the
surface carbonate species. We have evidenced that doxorubicin
enters into strong complexation interaction with coordinatively
unsaturated Zr4+ species without moving them away from the
surface (increased fluorescence) similar to that observed for
Mn2+ ions.45 This process perturbs, however, surface carbonate
species and transforms them into bridged carbonate (band
changes in FTIR spectra). The carrier particle retains its fluo-
rescent properties upon drug adsorption, and ursolic acid even
stabilizes the particles at physiological pH. Preliminary radiola-
beling and follow-up probes verified that the method is able to
carry out prospective SPECT/CT drug delivery follow-up studies
with the 99mTc-labelled ursolic acid-capped zirconia. The use of
such zirconia particles seems to be particularly interesting in the
future for topical radiotherapy with b-emitting isotopes that
induce fast degradation in polymeric nanocarriers.
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